Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effects of Antidepressants During Pregnancy and Lactation

Effects of Antidepressants During Pregnancy and Lactation Depression is one of the most common psychiatric disorders. A variety of different chemical structures have been found to have antidepressant activity. The number is constantly growing; however, as yet, no one group has been found to have a clear therapeutic advantage over the others. The major indication for antidepressant drugs is depression, but a number of side effects have been established by clinical experience and controlled trials. It is clear that, to some extent, any drug or chemical substance administered to the mother is able to cross the placenta unless it is destroyed or altered during metabolism. Placental transport of maternal substrates to the fetus and of substances from the fetus to the mother is established at about the fifth week of fetal life. Traditionally, teratogenic effects of antidepressants or other drugs have been noted as anatomic malformation. It is clear that these are dose- and time-related and that the fetus is at great risk during the first 3 months of gestation. However, it is possible for antidepressants to exert their effects on the fetus at other times during pregnancy as well as to infants during lactation. Administration of antidepressants to pregnant women presents a unique problem for the physician. Not only must maternal pharmacologic mechanisms be taken into consideration when prescribing an antidepressant drug, but the fetus must also be regarded as a potential recipient of the drug. Certain results are evident with regard to drugs administered during lactation. It is essential that physicians need to be aware of the results of animal studies in this area and of the potential risk of maternal drug ingestion to the suckling infant. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Effects of Antidepressants During Pregnancy and Lactation

Iqbal, Mohammad
Annals of Clinical Psychiatry , Volume 11 (4) – Sep 30, 2004
Download PDF
20 pages

Loading next page...
 
/lp/springer-journals/effects-of-antidepressants-during-pregnancy-and-lactation-eecXLIhPjx
Publisher
Springer Journals
Copyright
Copyright © 1999 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1022317630703
Publisher site
See Article on Publisher Site

Abstract

Depression is one of the most common psychiatric disorders. A variety of different chemical structures have been found to have antidepressant activity. The number is constantly growing; however, as yet, no one group has been found to have a clear therapeutic advantage over the others. The major indication for antidepressant drugs is depression, but a number of side effects have been established by clinical experience and controlled trials. It is clear that, to some extent, any drug or chemical substance administered to the mother is able to cross the placenta unless it is destroyed or altered during metabolism. Placental transport of maternal substrates to the fetus and of substances from the fetus to the mother is established at about the fifth week of fetal life. Traditionally, teratogenic effects of antidepressants or other drugs have been noted as anatomic malformation. It is clear that these are dose- and time-related and that the fetus is at great risk during the first 3 months of gestation. However, it is possible for antidepressants to exert their effects on the fetus at other times during pregnancy as well as to infants during lactation. Administration of antidepressants to pregnant women presents a unique problem for the physician. Not only must maternal pharmacologic mechanisms be taken into consideration when prescribing an antidepressant drug, but the fetus must also be regarded as a potential recipient of the drug. Certain results are evident with regard to drugs administered during lactation. It is essential that physicians need to be aware of the results of animal studies in this area and of the potential risk of maternal drug ingestion to the suckling infant.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Sep 30, 2004

References

  • Treatment guidelines for psychotropic drug use in pregnancy
    Cohen, LS; Heller, VL; Rosenbaum, JF
  • Psychiatric medication during pregnancy: Understanding and minimizing the risks
    Miller, LJ
  • The rational use of psychotropic drugs in pregnancy and postpartum
    Robinson, HE; Stewart, DE; Flak, E
  • Textbook of Psychopharmacology
    Stowe, ZN; Nemeroff, CB
  • Parent-and Child-Oriented Approaches
    Wisner, KL; Perel, JM
  • Pharmacokinetic pitfalls in the estimation of the breast milk plasma ration for drugs
    Wilson, JT; Brown, RD; Hinson, JL; Daily, JW
  • Adverse effects of drugs and chemicals in breast milk on the nursing infant
    Kacew, S
  • Drug use in the neonate: Inter-relationships of pharmacokinetics, toxicity and biochemical maturity
    Warner, A
  • Drugs in human milk: Clinical pharmacokinetic considerations
    Atkinson, HC; Begg, EJ; Darlow, BA
  • Excretion of drugs in human breast milk
    Welch, R; Findlay, J
  • Catalog of Teratogenic Agents
    Shepard, TH
  • Limb deformities associated with iminodibenzyl hydrochloride
    McBride, WG
  • Birth Defects and Drugs in Pregnancy
    Heeinonen, OP; Slone, D; Shapiro, S
  • Imipramine in pregnancy
    Kuenssberg, EV; Knox, JDE
  • Malformed infant
    Barson, AJ
  • Possible teratogenicity of imipramine/chloropyramine
    Idanpaan-Heikkila, J; Saxen, L
  • Imipramine in pregnancy
    Crombie, DL; Pinsent, R; Fleming, D
  • Imipramine and pregancy
    Sim, M
  • Use of antidepressant drugs during the first trimester
    Scanlon, FJ
  • Possible teratogenicity of tricyclic antidepressants
    Rachelefsky, GS; Flynt, JW; Eggin, AJ; Wilson, MG
  • Possible teratogenicity of tricyclic antidepressants
    Banister, P; Dafoe, C; Smith, ESO; Miller, J
  • Imipramine (Tofranil)
    Jacobs, D
  • Tricyclic antidepressant and limb reduction deformities
  • Imipramine and congenital abnormalities
    Morrow, AW
  • Present status of drugs as teratogens in man
    Wilson, JG
  • Medicaid antidepressants pregnancy exposure outcomes
    Rosa, F
  • Will this drug harm the unborn infant?
    Hill, RM
  • Withdrawal symptoms in neonate associated with maternal imipramine therapy
    Eggermont, E
  • Agoraphobia and imipramine withdrawal?
    Shrand, H
  • The transfer of drugs and other chemicals into human milk
  • Excretion of imipramine and desipramine in human breast milk
    Sovner, R; Orsulak, PJ
  • Tricyclics and breast feeding
    Erickson, SH; Smith, GH; Heidrich, F
  • Withdrawal symptoms in neonates associated with maternal antidepressant therapy
    Webster, PA
  • Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant's serum
    Stancer, HC; Reed, KL
  • Teratogenicity of psychotherapeutic medication
    Elia, J; Katz, IR; Simpson, GM
  • Limb deformities: Possible association with drugs
    Freeman, R.
  • Bilateral clinical anopthalmia: Drugs as potential factors
    Golden, SM; Perman, KI
  • Amitriptyline/perphenazine maternal overdose and birth defects
    Wertelecki, W; Purvis Smith, SG; Blackburn, WR
  • Thanatophoric dwarfism—-drugs and antenatal diagnosis: A case report
    Rafla, NM; Meehan, FP
  • Amitriptyline in human breast milk and the nursing infant's serum
    Bader, TF; Newman, K
  • Drug excretion in human breast milk. Principles, pharmacokinetics and projected consequences
    Wilson, JT; Brown, D; Cherek, DR; Dailey, JW; Hilman, B; Jobe, PC; Manno, BR; Manno, JE; Redetzki, HM; Strewart, JJ
  • Amitriptyline and nortriptyline excretion in human breast milk
    Brixen-Rasmussen, L; Halgrener, J; Jorgensen, A
  • Antidepressant teratogenicity
    Bourke, GM
  • Urinary retention in a neonate secondary to maternal ingestion of nortriptyline
    Shearer, WT; Schreiner, RL; Marshall, RE
  • Milk concentrations of flupenthixol, nortriptyline and zuclopenthixol and between-breast differences in two patients
    Matheson, I; Skjaeraasen, J
  • Serum nortriptyline levels in nursing mothers and their infants
    Wisner, KL; Perel, JM
  • Effects of doxepin hydrochloride administered to pregnant rats upon the fetuses and their postnatal development
    Owaki, Y; Momiyama, H; Onodera, N
  • Effects of doxepin hydrochloride administered to pregnant rabbits upon the fetuses
    Owaki, Y; Momiyama, H; Onodera, N
  • Small left colon syndrome associated with maternal ingestion of psychotropic drugs
    Falterman, CG; Richardson, CJ
  • Respiratory depression caused by N-desmethyldoxepin in human milk
    Matheson, I; Pande, H; Alertsen, AR
  • Excretion of doxepin and N-desmethyldoxepin in human milk
    Kemp, J; Ilett, KF; Booth, J; Hackett, LP
  • Toxicological studies of clomipramine hydrochloride
    Watenabe, N; Nakai, T; Iwanami, K; Fujii, T
  • Neonatal effects of maternal clomipramine treatment
    Ben Muza, A; Smith, CS
  • Toxic neonatal effects following maternal clomipramine therapy
    Schimmell, MS; Katz, EZ; Shaag, Y; Pastuszak, A; Koren, G
  • Neonatal effects of maternal clomipramine treatment
    Ostergaard, GZ; Pedersen, SE
  • Neonatal convulsions caused by withdrawal from maternal clomipramine
    Cowe, L; Lloyd, DJ; Dawling, S
  • Current Psychotherapic Drugs
    Donald, FK; Lewis, PR
  • Therapeutic Drugs
    Sir, CD
  • The safety of fluoxetine—-an update
    Cooper, GL
  • Placental transfer and fetal distribution of fluoxetine in the rat
    Pohland, RC; Bryd, TK; Hamilton, M; Koons, JR
  • Birth outcomes in pregnant women taking fluoxetine
    Christina, DC; Kathleen, AJ; Lyn, MD; Robert, JF; Kenneth, LJ
  • Fluoxetine hydrochloride (Prozac) toxicity in a neonate
    Spencer, DJ
  • Importance of duration of drug action in the antagonism of p-choroamphetamine depletion of brain serotonin—-comparison of fluoxetine and chlorimipramine
    Fuller, RW; Snoddy, HD; Perry, KW; Bymaster, FP; Wong, DT
  • Effects of third trimester fluoxetine exposure on the newborn
    David, JG
  • Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)
    Pastuszak, A; Schick-Boschetto, B; Zuber, C; Feldkamp, M; Pinelli, M; Sihn, S; Donnenfeld, A; McCormack, M; Leen-Mitchell, M; Woodland, C; Gardner, A; Hom, M; Koren, G
  • Excretion of fluoxetine in human breast milk
    Isenberg, KE
  • Antidepressant treatment during breast-feeding
    Katherine, LW; James, MP; Robert, LF
  • Sertraline and desmethylsertraline in human breast milk and nursing infants
    Stowe, ZN; Owens, MJ; Landry, JC; Kilts, CD; Ely, T; Llewellyn, A; Nemeroff, CB
  • Teratogenicity of maprotiline tested by oral administration to mice and rats
    Esaki, K; Tanioka, Y; Tsukada, M; Izumiyama, K
  • Excretion of trazodone in breast milk
    Verbeeck, RK; Ross, SG; McKenna, EA
  • Buproprion: A chemically and pharmacologically unique antidepressant
    Weintraub, M; Evan, P
  • Excretion of buproprion in breast milk
    Briggs, GG; Samson, JH; Ambrose, PJ; Schroeder, DH
  • Amoxapine, a new antidepressant, appears in human milk
    Gelenberg, AJ
  • Prenatal and postnatal depression among low income Brazilian women
    Da-Silva, VA; Moraes-Santos, AR; Carvalho, MS; Teixeira, NA
  • Prevalence and background factors of maternity blues
    Murata, A; Nadaoka, T; Morioka, Y; Oiji, A; Saito, H
  • Postpartum mood disorders: Diagnosis and treatment guidelines
    Nonacs, R; Cohen, LS
  • Postpartum mood disorders: Clinical perspectives
    Pariser, SF; Nasrallah, HA; Gardner, DK